Objective: To identify the antiviral antioxidant and toxicological evaluation of marine halophyte.Methods:Mangrove associates such as Salicornia brachiata, Clerodendron inerme, Rhizophora lamarckii, Suaeda maritima were collected. In vitro antiviral studies such as HBsAg binding assay, DNA polymerase inhibition assay, RT inhibition assay were carried out. Moreover, antioxidant properties, ash content, elemental analysis, LD50 analysis were measured for theS. maritima leaf extract which was the most potent. Results: S. maritima leaf extract showed minimum concentration of IC50 value with HBsAg binding assay, DNA polymerase inhibition assay, RT inhibition assay as 325.98, 843.09 and 587.32 μg/ml concentrations respectively. Antioxidant properties of S. maritima leaf extract showed the minimum concentration (23.64±5.27μg/ml) of IC50 value with the nitric oxide scavenging assay, followed by DPPH assay (112.03±18.39μg/ml). The ash content of S. maritima leaf extract was varied between 8.05% to 87.30%concentrations. The elemental analysis of S. maritima showed the values within the limits of WHO guidelines. The lethal dose of S. maritima leaf extract was identified as 3000 mg/kg/body weight. The sub acute toxicity was not showed any significant differences with organ weights between control and extract treated animals. Biochemical parameters such as SGOT, SGPT, ALP, sugar and urea were not showed any significant variations between control and extract treated animals. But, the results of haematological parameters such as WBC (6600±234.90 cells/cumm), lymphocytes (69±14.09), polymorphs (38±9.38), eosinophils (02±0.00) were found significantly increased with extract treated animals. Phytochemical analysis of S. maritima leaf extract showed the presence of various phytochemical constituents such as reducing sugars, polyophenols, flavonoids and tannins with the leaf extract. Conclusions: The results of the present findings pave the way for the identification of novel molecules for the possible utilization of antiviral and antioxidant drugs from Suaeda maritima leaf.

The unprecedented COVID-19 pandemic situation forced the scientific community to explore all the possibilities from various fields, and so far we have seen a lot of surprises, eureka moments and disappointments. One of the approaches from the cellular therapists was exploiting the immunomodulatory and regenerative potential of mesenchymal stromal cells (MSCs), more so of MSC-derived extracellular vesicles (EVs)—particularly exosomes, in order to alleviate the cytokine storm and regenerate the damaged lung tissues. Unlike MSCs, the EVs are easier to store, deliver, and are previously shown to be as effective as MSCs, yet less immunogenic. These features attracted the attention of many and thus led to a tremendous increase in publications, clinical trials and patent applications. This review presents the current landscape of the field and highlights some interesting findings on MSC-derived EVs in the context of COVID-19, including in silico, in vitro, in vivo and case reports. The data strongly suggests the potential of MSC-derived EVs as a therapeutic regime for the management of acute lung injury and associated complications in COVID-19 and beyond.